The president of the Chinese pharmaceutical company Sinovac, Yin Weidong, assured this Thursday that his vaccine against the coronavirus, one of the most advanced in the world, may begin to be applied en masse to the population to early next year.
During a visit by Efe and other media to the laboratories and the company’s factory in Beijing, Yin said that its factory has the capacity to produce 300 million doses per year of the vaccine, called CoronaVac.
The company began to build a specific factory in March to produce this vaccine against the coronavirus, which already has been producing doses for several weeks. Yin explained that they tried seven different vaccine methods, but found that “the inactivated vaccine route was the best.”
He assured that the tests carried out in phase 3 on those over 18 years “They have not shown any special adverse reactions”, and affirmed that its vaccine is capable of “fighting all the strains of the coronavirus SARS-Cov-2 existing in the world”. CoronaVac is now being tested in Brazil, Turkey, Bangladesh and Indonesia: “It is better to test abroad because in China the pandemic is practically controlled and it would be difficult to test its effectiveness here“added the president of Sinovac.
Yin indicated that the possibility that his vaccine could be manufactured in other countries is also being studied. Sinovac announced on September 9 that the results of the CoronaVac vaccine trials in phases 1 and 2 had shown “good safety and immunogenicity” in healthy adults over the age of 60 as they did in people between the ages of 18 and 59.
Antibody levels in those over 60 were slightly lower than those found in tests with a younger population, according to the company. Ensure that the vaccine can be applied to the entire population, including children and adolescents, is one of the keys to preventing outbreaks of the virus in schools and daycare centers.
The Sinovac vaccine, which is produced in Latin America in cooperation with the Brazilian institute Butantan, based in Sao Paulo, is in the last phase of large-scale adult trials in countries such as Brazil, Indonesia or Turkey. CoronaVac has 46 million doses insured in the South American country until December and another 16 million for the first quarter of 2021, according to Brazilian authorities.
Near to 90% of Chinese pharmaceutical employees worldwide and their families have received their doses, according to the company. Four Chinese vaccines are currently in phase 3 of clinical trials – among a total of nine in the world – although one of the remaining five is part of a consortium formed by the Chinese Fosun Pharma, the German Biontech and the American Pfizer.
The four totally Chinese are those from Sinovac, Sinopharm, the Wuhan Institute of Biological Products and the one from Cansino Biologics, which began to be used in late June. in the chinese army.